Centessa IPO Presentation Deck

Lixivaptan: Phase 3 Pivotal Trial Design Part 1 Screening Placebo Baseline measurements x 2:1 Randomization of 1200 subjects Lixivaptan Placebo H Double-blind treatment period Primary endpoint • Annualized change in eGFR from baseline to follow-up in Part 1 No drug 52-week measurements Endpoint comparisons Part 2 Lixivaptan Lixivaptan All patients participating in Part 1 will continue to Part 2 of study Open label maintenance period (52 weeks) No drug PALLADIO BIOSCIENCES Final measurements Key secondary endpoints • Incidence of serum ALT levels 3 x ULN in participants randomized to lixivaptan compared to those randomized to placebo in Part 1 Annualized change in eGFR from baseline to follow-up in Part 2 • Annualized rate of change (slope) in eGFR, based on all eGFR determinations during the double-blind, randomized treatment period in Part 1 X CENTESSA 15

View entire presentation